MetaADEDB 2.0 @ LMMD
Vosevi
(FMWRYUBVSONSCK-ZYTFCPLVSA-N)
Structure
SMILES
CC(OC(=O)[C@@H](N[P@@](=O)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)F)n1ccc(=O)[nH]c1=O)C)C.CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(c1c(O2)nc2cc(OC)ccc2n1)(F)F)C(C)(C)C.COC[C@H]1C[C@H](N(C1)C(=O)[C@@H](c1ccccc1)NC(=O)OC)c1ncc([nH]1)c1ccc2c(c1)COc1c2cc2ccc3c(c2c1)nc([nH]3)[C@@H]1CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C
Molecular Formula:
C111H135F5N17O26PS
Molecular Weight:
2281.390
Log P:
17.5223
Hydrogen Bond Acceptor:
40
Hydrogen Bond Donor:
10
TPSA:
564.69
CAS Number(s):
N/A
Synonym(s)
1.
Vosevi
External Link(s)
PubChem Compound129011857
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1FatigueFAERS: 115US FAERS
2HeadacheFAERS: 78US FAERS
3NauseaFAERS: 51US FAERS
4treatment failureFAERS: 34US FAERS
5Drug ineffectiveFAERS: 23US FAERS
6Hepatitis CFAERS: 23US FAERS
7Drug dose omissionFAERS: 13US FAERS
8VomitingFAERS: 13
Canada Vigilance: 1		Canada Vigilance
US FAERS
9DyspepsiaFAERS: 12US FAERS
10Abdominal discomfortFAERS: 9US FAERS
11PruritusFAERS: 9US FAERS
12ArthralgiaFAERS: 8US FAERS
13Product dose omissionFAERS: 7US FAERS
14Hepatitis C virus test positiveFAERS: 6US FAERS
15Abdominal PainFAERS: 5US FAERS
16AstheniaFAERS: 5US FAERS
17ConstipationFAERS: 5US FAERS
18DizzinessFAERS: 5US FAERS
19Memory impairmentFAERS: 5US FAERS
20Product use complaintFAERS: 5US FAERS
21InfluenzaFAERS: 4US FAERS
22Intentional dose omissionFAERS: 4US FAERS
23MyalgiaFAERS: 4US FAERS
24PainFAERS: 4US FAERS
25Urinary tract infectionFAERS: 4US FAERS
26Weight decreasedFAERS: 4US FAERS
27Chest PainFAERS: 3US FAERS
28Drug resistanceFAERS: 3US FAERS
29Feeling abnormalFAERS: 3US FAERS
30Genotype drug resistance test positiveFAERS: 3US FAERS
31NasopharyngitisFAERS: 3US FAERS
32Peripheral swellingFAERS: 3US FAERS
33Accidental overdoseFAERS: 2US FAERS
34AcneFAERS: 2US FAERS
35AngerFAERS: 2US FAERS
36Blood glucose increasedFAERS: 2US FAERS
37Extra dose administeredFAERS: 2US FAERS
38Hepatitis C RNA positiveFAERS: 2US FAERS
39Inappropriate schedule of drug administrationFAERS: 2US FAERS
40Intentional product use issueFAERS: 2US FAERS
41MalaiseFAERS: 2US FAERS
42Maternal exposure during pregnancyFAERS: 2US FAERS
43Middle insomniaFAERS: 2US FAERS
44Musculoskeletal PainFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
45Musculoskeletal discomfortFAERS: 2US FAERS
46NephrolithiasisFAERS: 2US FAERS
47OverdoseFAERS: 2US FAERS
48Portal hypertensive gastropathyFAERS: 2US FAERS
49Rheumatoid ArthritisFAERS: 2US FAERS
50SomnolenceFAERS: 2US FAERS
51VasculitisFAERS: 2US FAERS
52Wrong technique in product usage processFAERS: 2US FAERS
53Accidental exposure to productFAERS: 1US FAERS
54AgeusiaFAERS: 1US FAERS
55Alanine Aminotransferase IncreasedFAERS: 1US FAERS
56AlopeciaFAERS: 1US FAERS
57Ammonia increasedFAERS: 1US FAERS
58Anal erosionFAERS: 1US FAERS
59Angina PectorisFAERS: 1US FAERS
60BedriddenFAERS: 1US FAERS
61Blood count abnormalFAERS: 1US FAERS
62Blood testosterone decreasedFAERS: 1US FAERS
63Bowel movement irregularityFAERS: 1US FAERS
64BradycardiaFAERS: 1US FAERS
65Cerebrovascular accidentFAERS: 1US FAERS
66Chest discomfortFAERS: 1US FAERS
67ChromaturiaFAERS: 1US FAERS
68Clostridium test positiveFAERS: 1US FAERS
69Dermatitis acneiformFAERS: 1US FAERS
70Drug dispensing errorFAERS: 1US FAERS
71Dry skinFAERS: 1US FAERS
72DyschromatopsiaFAERS: 1US FAERS
73DysgeusiaFAERS: 1US FAERS
74Emotional distressFAERS: 1US FAERS
75EpistaxisFAERS: 1US FAERS
76EructationFAERS: 1US FAERS
77Eye infection syphiliticFAERS: 1US FAERS
78Eye inflammationFAERS: 1US FAERS
79Eye irritationFAERS: 1US FAERS
80Factor VIII DeficiencyFAERS: 1US FAERS
81FlatulenceFAERS: 1US FAERS
82FlushingFAERS: 1US FAERS
83Food PoisoningFAERS: 1US FAERS
84Gene MutationFAERS: 1US FAERS
85GlomerulonephritisFAERS: 1US FAERS
86Hepatic vascular thrombosisFAERS: 1US FAERS
87Hepatitis B surface antigen negativeFAERS: 1US FAERS
88HypersomniaFAERS: 1US FAERS
89HypotensionFAERS: 1US FAERS
90IncontinenceFAERS: 1US FAERS
91Increased tendency to bruiseFAERS: 1US FAERS
92InfectionFAERS: 1US FAERS
93InflammationFAERS: 1US FAERS
94Insurance issueFAERS: 1US FAERS
95Joint swellingFAERS: 1US FAERS
96LethargyFAERS: 1US FAERS
97Lower respiratory tract infectionFAERS: 1US FAERS
98LymphomaFAERS: 1US FAERS
99MYELODYSPLASTIC SYNDROMEFAERS: 1US FAERS
100Mood swingsFAERS: 1US FAERS
101Myasthenia GravisFAERS: 1US FAERS
102Nephrotic SyndromeFAERS: 1US FAERS
103Night sweatsFAERS: 1US FAERS
104OligodipsiaFAERS: 1US FAERS
105PalpitationsFAERS: 1US FAERS
106PancreatitisFAERS: 1US FAERS
107Portal HypertensionFAERS: 1US FAERS
108Product use issueFAERS: 1US FAERS
109Productive CoughFAERS: 1US FAERS
110Renal transplant failureFAERS: 1US FAERS
111Septic ShockFAERS: 1US FAERS
112Spinal cord abscessFAERS: 1US FAERS
113StressFAERS: 1US FAERS
114SyncopeFAERS: 1US FAERS
115TachycardiaFAERS: 1US FAERS
116Therapeutic response unexpectedFAERS: 1US FAERS
117Therapy cessationFAERS: 1US FAERS
118Therapy non-responderFAERS: 1US FAERS
119Throat irritationFAERS: 1US FAERS
120ThrombosisFAERS: 1US FAERS
121TremorFAERS: 1US FAERS
122UrticariaFAERS: 1US FAERS
123Viral load increasedFAERS: 1US FAERS
124White blood cell count decreasedFAERS: 1US FAERS
125Wrong scheduleFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.